Genmab A/S (GMAB)
| Market Cap | 30.55B |
| Revenue (ttm) | 1.17B |
| Net Income (ttm) | 402.08M |
| Shares Out | 653.86M |
| EPS (ttm) | 0.59 |
| PE Ratio | 78.60 |
| Forward PE | 55.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 203,258 |
| Open | 46.50 |
| Previous Close | 46.39 |
| Day's Range | 46.45 - 46.88 |
| 52-Week Range | 30.10 - 49.07 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | 42.14 (-9.8%) |
| Est. Earnings Date | Nov 10, 2021 |
About GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for tr...
Financial Performance
In 2020, Genmab A/S's revenue was 10.11 billion, an increase of 88.43% compared to the previous year's 5.37 billion. Earnings were 4.76 billion, an increase of 119.67%.
Financial numbers in millions DKKFinancial StatementsAnalyst Forecast
According to 7 analysts, the average rating for Genmab A/S stock is "Buy." The 12-month stock price forecast is 42.14, which is a decrease of -9.82% from the latest price.
News
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Company Announcement
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NMEs...
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immuno...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational therapies and technologies in the company's solid tumor product...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer
The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S' (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent or metast...
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurr...
COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated a...
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurr...
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated a...
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV) in re...
Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treat...
Media Release
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hod...
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/...
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hod...
NORTH CHICAGO, Ill., and COPENHAGEN, Denmark, Sept, 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part...
Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Media Release Copenhagen, Denmark, 2 7 August, 202 1
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
Genmab Announces Financial Results for the First Half of 2021
August 1 1 , 20 2 1 ; Copenhagen, Denmark; Interim Report for the First Half of 20 2 1
Is a Surprise Coming for Genmab (GMAB) This Earnings Season?
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
Company Announcement
Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs
Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
ALXN or GMAB: Which Is the Better Value Stock Right Now?
ALXN vs. GMAB: Which Stock Is the Better Value Option?
Transactions in connection with share buy-back program
Company Announcement
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous...
Company Announcement